Novartis Gets First-Mover Advantage With FDA Approval Of Cosentyx For Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Secukinumab gets to market before competing IL-17 inhibitors from Lilly and AstraZeneca/Amgen are even filed for approval. Wall Street is expecting blockbuster sales for psoriasis agents that can improve upon the performance of TNF inhibitors.
You may also be interested in...
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
AbbVies Rinvoq Succeeds Against The Odds In Phase II Lupus Trial
Despite a troubled history of JAK inhibitors in lupus trials, AbbVie’s Rinvoq has hit the mark in a mid-stage study of the condition, shifting focus to a pivotal program that could expand the blockbuster drug’s reach.
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.